Literature DB >> 22263081

Stereotactic ablative radiotherapy (SABR) for lung cancer: What does the future hold?

Billy W Loo1.   

Abstract

Entities:  

Year:  2011        PMID： 22263081      PMCID： PMC3256516          DOI： 10.3978/j.issn.2072-1439.2011.06.08

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  16 in total

1.  Stereotactic body radiation therapy for inoperable early stage lung cancer.

Authors:  Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

2.  Stereotactic ablative radiotherapy for stage I NSCLC: Recent advances and controversies.

Authors:  Suresh Senan; David A Palma; Frank J Lagerwaard
Journal:  J Thorac Dis       Date:  2011-09       Impact factor: 2.895

3.  Stereotactic ablative radiotherapy: what's in a name?

Authors:  Billy W Loo; Joe Y Chang; Laura A Dawson; Brian D Kavanagh; Albert C Koong; Suresh Senan; Robert D Timmerman
Journal:  Pract Radiat Oncol       Date:  2011-01-14

4.  Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer.

Authors:  J Martin Brown; Maximilian Diehn; Billy W Loo
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-01       Impact factor: 7.038

5.  Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data.

Authors:  R Arriagada; A Auperin; S Burdett; J P Higgins; D H Johnson; T Le Chevalier; C Le Pechoux; M K B Parmar; J P Pignon; R L Souhami; R J Stephens; L A Stewart; J F Tierney; H Tribodet; J van Meerbeeck
Journal:  Lancet       Date:  2010-03-24       Impact factor: 79.321

Review 6.  Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications.

Authors:  Alexander Chi; Zhongxing Liao; Nam P Nguyen; Jiahong Xu; Baldassarre Stea; Ritsuko Komaki
Journal:  Radiother Oncol       Date:  2010-01-13       Impact factor: 6.280

7.  Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer.

Authors:  Frank J Lagerwaard; Cornelis J A Haasbeek; Egbert F Smit; Ben J Slotman; S Senan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-12-31       Impact factor: 7.038

8.  Future of cancer incidence in the United States: burdens upon an aging, changing nation.

Authors:  Benjamin D Smith; Grace L Smith; Arti Hurria; Gabriel N Hortobagyi; Thomas A Buchholz
Journal:  J Clin Oncol       Date:  2009-04-29       Impact factor: 44.544

9.  Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients.

Authors:  H Blomgren; I Lax; I Näslund; R Svanström
Journal:  Acta Oncol       Date:  1995       Impact factor: 4.089

10.  Dosimetric evaluation of heterogeneity corrections for RTOG 0236: stereotactic body radiotherapy of inoperable stage I-II non-small-cell lung cancer.

Authors:  Ying Xiao; Lech Papiez; Rebecca Paulus; Robert Timmerman; William L Straube; Walter R Bosch; Jeff Michalski; James M Galvin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-03-15       Impact factor: 7.038
View more
  7 in total

1.  Additional data in the debate on stage I non-small cell lung cancer: surgery versus stereotactic ablative radiotherapy.

Authors:  Charles B Simone; Jay F Dorsey
Journal:  Ann Transl Med       Date:  2015-08

2.  Stereotactic ablative radiotherapy (SABR) in operable early stage non-small cell lung cancer (NSCLC) patients: challenge to claim being undisputed gold standard.

Authors:  Deniz Yalman; Ugur Selek
Journal:  Ann Transl Med       Date:  2015-07

3.  Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions.

Authors:  Alexander Filatenkov; Jeanette Baker; Antonia M S Mueller; Justin Kenkel; G-One Ahn; Suparna Dutt; Nigel Zhang; Holbrook Kohrt; Kent Jensen; Sussan Dejbakhsh-Jones; Judith A Shizuru; Robert N Negrin; Edgar G Engleman; Samuel Strober
Journal:  Clin Cancer Res       Date:  2015-04-13       Impact factor: 12.531

Review 4.  Interventional oncology in multidisciplinary cancer treatment in the 21(st) century.

Authors:  Andreas Adam; Lizbeth M Kenny
Journal:  Nat Rev Clin Oncol       Date:  2014-12-02       Impact factor: 66.675

5.  Clinical outcome of hypofractionated breath-hold image-guided SABR of primary lung tumors and lung metastases.

Authors:  Judit Boda-Heggemann; Anian Frauenfeld; Christel Weiss; Anna Simeonova; Christian Neumaier; Kerstin Siebenlist; Ulrike Attenberger; Claus Peter Heußel; Frank Schneider; Frederik Wenz; Frank Lohr
Journal:  Radiat Oncol       Date:  2014-01-08       Impact factor: 3.481

6.  Real-time high spatial resolution dose verification in stereotactic motion adaptive arc radiotherapy.

Authors:  Mitchell Duncan; Matthew K Newall; Vincent Caillet; Jeremy T Booth; Paul J Keall; Michael Lerch; Vladimir Perevertaylo; Anatoly B Rosenfeld; Marco Petasecca
Journal:  J Appl Clin Med Phys       Date:  2018-06-05       Impact factor: 2.102

7.  Molecular Magnetic Resonance Imaging of Tumor Response to Therapy.

Authors:  Adam J Shuhendler; Deju Ye; Kimberly D Brewer; Magdalena Bazalova-Carter; Kyung-Hyun Lee; Paul Kempen; K Dane Wittrup; Edward E Graves; Brian Rutt; Jianghong Rao
Journal:  Sci Rep       Date:  2015-10-06       Impact factor: 4.379
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.